JPS62152B2 - - Google Patents
Info
- Publication number
- JPS62152B2 JPS62152B2 JP4243377A JP4243377A JPS62152B2 JP S62152 B2 JPS62152 B2 JP S62152B2 JP 4243377 A JP4243377 A JP 4243377A JP 4243377 A JP4243377 A JP 4243377A JP S62152 B2 JPS62152 B2 JP S62152B2
- Authority
- JP
- Japan
- Prior art keywords
- nitrophenyl
- pyrazolo
- pyrimidine
- amino
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 1 -Nitrophenyl-pyrazolo[3.4-d]pyrimidine derivative Chemical class 0.000 claims description 12
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- OEICGMPRFOJHKO-UHFFFAOYSA-N 2-(ethoxymethylidene)propanedinitrile Chemical compound CCOC=C(C#N)C#N OEICGMPRFOJHKO-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- LGROKZMEHJZWDU-UHFFFAOYSA-N n-amino-n-phenylnitramide Chemical compound [O-][N+](=O)N(N)C1=CC=CC=C1 LGROKZMEHJZWDU-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- FRBUNLLUASHNDJ-UHFFFAOYSA-N (2-nitrophenyl)hydrazine Chemical compound NNC1=CC=CC=C1[N+]([O-])=O FRBUNLLUASHNDJ-UHFFFAOYSA-N 0.000 description 1
- NFVAFEQWWNNKLX-UHFFFAOYSA-N 1-(4-nitrophenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CC=2C(N)=NC=NC=2N1C1=CC=C([N+]([O-])=O)C=C1 NFVAFEQWWNNKLX-UHFFFAOYSA-N 0.000 description 1
- NUGZBVBZIDWZAD-UHFFFAOYSA-N 1h-pyrazole-4-carbonitrile Chemical compound N#CC=1C=NNC=1 NUGZBVBZIDWZAD-UHFFFAOYSA-N 0.000 description 1
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 description 1
- FFNKBQRKZRMYCL-UHFFFAOYSA-N 5-amino-1h-pyrazole-4-carbonitrile Chemical compound NC1=NNC=C1C#N FFNKBQRKZRMYCL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4243377A JPS53127492A (en) | 1977-04-13 | 1977-04-13 | 1100nitrophenyll44elaidamidee pyrazolo*3*44d*pyrimidine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4243377A JPS53127492A (en) | 1977-04-13 | 1977-04-13 | 1100nitrophenyll44elaidamidee pyrazolo*3*44d*pyrimidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53127492A JPS53127492A (en) | 1978-11-07 |
| JPS62152B2 true JPS62152B2 (US06272168-20010807-M00014.png) | 1987-01-06 |
Family
ID=12635926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4243377A Granted JPS53127492A (en) | 1977-04-13 | 1977-04-13 | 1100nitrophenyll44elaidamidee pyrazolo*3*44d*pyrimidine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS53127492A (US06272168-20010807-M00014.png) |
-
1977
- 1977-04-13 JP JP4243377A patent/JPS53127492A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS53127492A (en) | 1978-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3219235B2 (ja) | 白金錯体 | |
| JP3697210B2 (ja) | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 | |
| CN112961120B (zh) | 一种萘基脲类化合物、其制备方法及应用 | |
| AU2018403404B2 (en) | Compound and use thereof in medicine | |
| JPS6225670B2 (US06272168-20010807-M00014.png) | ||
| JP2005516938A5 (US06272168-20010807-M00014.png) | ||
| US4843161A (en) | Platinum-intercalative complexes for the treatment of cancer | |
| TW201734028A (zh) | 抑制癌症及病毒之化合物 | |
| WO2012155559A1 (zh) | 有机杂化四核铂配合物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN114605407B (zh) | 一种吲哚喹啉酮类化合物及其合成方法和应用 | |
| EP1043316B1 (en) | Nitroimidazole derivatives as sensitivity enhancers for chemotherapy and radiotherapy | |
| JPH02189A (ja) | １‐アミノメチルホスホン酸誘導体、その製造法および医薬組成物 | |
| HUT67899A (en) | Thioxanthenone antitumor agents | |
| JPS62152B2 (US06272168-20010807-M00014.png) | ||
| AU2005318227B2 (en) | Stereoselective process and crystalline forms of a camptothecin | |
| CN116096372A (zh) | 一种egfr抑制剂、其制备方法和在药学上的应用 | |
| WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
| JPH01165586A (ja) | 抗腫瘍プロドラッグ | |
| EP3596054B1 (en) | 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments | |
| JP2003506332A (ja) | 経口投与活性のあるビス白金錯体 | |
| CN112266396B (zh) | 一种基于生物正交化学的整合型前药、制备方法及其医药用途 | |
| JP5249753B2 (ja) | ジカルボン酸誘導体、転移阻害剤および抗腫瘍調製物の化学療法活性を増大する薬剤、細胞増殖抑制剤の効果を増大する方法および転移プロセスの阻害のための方法 | |
| CN111039940B (zh) | 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途 | |
| JPS6047272B2 (ja) | １−ニトロフェニル−４−オレオアミド−ピラゾロ〔３，４−ｄ〕ピリミジン | |
| CN116253695A (zh) | Hsp90抑制剂及其制备方法和用途 |
